Literature DB >> 12116252

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.

Karen Staehling-Hampton1, Sean Proll, Bryan W Paeper, Lei Zhao, Patrick Charmley, Analisa Brown, Jessica C Gardner, David Galas, Randall C Schatzman, Peter Beighton, Socrates Papapoulos, Herman Hamersma, Mary E Brunkow.   

Abstract

Van Buchem disease is an autosomal recessive sclerosing bone dysplasia characterized by skeletal hyperostosis, overgrowth of the mandible, and a liability to entrapment of the seventh and eighth cranial nerves. The genetic determinant maps to chromosome 17q12-q21. We refined the critical interval to the < 1-Mb region between D17S2250 and D17S2253 in 15 affected individuals, all of whom shared a common disease haplotype. Furthermore, we report here the identification of a 52-kb deletion located within the interval and encompassing D17S1789 that is 100% concordant with the disorder. Although the deletion itself does not appear to disrupt the coding region of any known or novel gene(s), the closest flanking genes are MEOX1 on the proximal side, and SOST on the distal side of the deletion. MEOX1 is known to be important for the development of the axial skeleton, whereas the SOST gene is the determinant of sclerosteosis, a disorder that shares many features with van Buchem disease, thus raising the possibility that van Buchem disease results from dysregulation of the expression of one or both of these genes. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116252     DOI: 10.1002/ajmg.10401

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  117 in total

Review 1.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 2.  Building strong bones: molecular regulation of the osteoblast lineage.

Authors:  Fanxin Long
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

Review 3.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

Review 4.  Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-04       Impact factor: 5.346

5.  Association between sclerostin and bone density in chronic spinal cord injury.

Authors:  Leslie R Morse; Supreetha Sudhakar; Valery Danilack; Carlos Tun; Antonio Lazzari; David R Gagnon; Eric Garshick; Ricardo A Battaglino
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

Review 6.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 7.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

8.  Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Authors:  Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin
Journal:  Genome Res       Date:  2005-06-17       Impact factor: 9.043

9.  Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Authors:  Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

Review 10.  Exploiting the WNT Signaling Pathway for Clinical Purposes.

Authors:  Mark L Johnson; Robert R Recker
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.